Page last updated: 2024-10-31

metoprolol and ANS (Autonomic Nervous System) Diseases

metoprolol has been researched along with ANS (Autonomic Nervous System) Diseases in 5 studies

Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Man in't Veld, AJ1
Boomsma, F1
Schalekamp, MA1
Pasquina, PF1
Houston, RM1
Belandres, PV1
de Milliano, PA1
van Eck-Smit, BL1
de Groot, AC1
Lie, KI1
Forslund, L1
Björkander, I1
Ericson, M1
Held, C1
Kahan, T1
Rehnqvist, N1
Hjemdahl, P1
Rochette, G1
Lecomte, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364]Phase 215 participants (Anticipated)Interventional2022-09-23Recruiting
The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096]Phase 215 participants (Anticipated)Interventional2019-04-04Recruiting
Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073]Phase 22 participants (Actual)Interventional2012-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Number of Absence Seizures From Week 8 (Baseline) to Week 12

The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12

InterventionAbscence seizures (Number)
Week 8 Baseline165
Week 12 Verapamil 4mg/kg/Day101

Change in Number of General Tonic-clonic Seizures From Week 8 (Baseline) Visit to Week 12 Visit

The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12

InterventionGeneral tonic-clonic seizures (Number)
Week 8 Baseline39
Week 12 Verapamil 4mg/kg/Day14

Change in Number of Myoclonic Seizures From Week 8 (Baseline) to Week 12

The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12

InterventionMyoclonic seizures (Number)
Week 8 Baseline116
Week 12 Verapamil 4mg/kg/Day175

Trials

1 trial available for metoprolol and ANS (Autonomic Nervous System) Diseases

ArticleYear
Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.
    Heart (British Cardiac Society), 2002, Volume: 87, Issue:5

    Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Biomarkers;

2002

Other Studies

4 other studies available for metoprolol and ANS (Autonomic Nervous System) Diseases

ArticleYear
Effects of beta-adrenoceptor agonists and antagonists in patients with peripheral autonomic neuropathy.
    British journal of clinical pharmacology, 1982, Volume: 13, Issue:Suppl 2

    Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Albuterol; Amyloidosis; Autonomi

1982
Beta blockade in the treatment of autonomic dysreflexia: a case report and review.
    Archives of physical medicine and rehabilitation, 1998, Volume: 79, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Autonomic Nervous System Diseases; Cervica

1998
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
    Circulation, 2000, Nov-14, Volume: 102, Issue:20

    Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp

2000
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
    Circulation, 2000, Nov-14, Volume: 102, Issue:20

    Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp

2000
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
    Circulation, 2000, Nov-14, Volume: 102, Issue:20

    Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp

2000
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
    Circulation, 2000, Nov-14, Volume: 102, Issue:20

    Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp

2000
[Several cardiovascular manifestations induced by vibrational stimuli].
    Comptes rendus des seances de la Societe de biologie et de ses filiales, 1985, Volume: 179, Issue:4

    Topics: Adult; Autonomic Nervous System Diseases; Cardiovascular Diseases; Fingers; Humans; Hypertension; Me

1985